natgillin/translations-raw huggingface dataset:
The HORIZONS Trial (Patients with STEMI undergoing primary PCI)
Preskušanje HORIZONS (Bolniki s SEMI pri katerih se je izvedla primarna PCI)
The hormonal active compounds in the tablet may have harmful effects if reaching the aquatic environment.
Hormonsko aktivne učinkovine v tableti imajo lahko škodljiv učinek, če pridejo v okoljske vode.
The hormonal contraceptive should contain at least 30 µg ethinylestradiol and contain norgestimate as the progestagen or patients should use an alternative reliable method of contraception (see sections 4.4 and 4.6).
Hormonski kontraceptiv mora vsebovati vsaj 30 µg etinilestradiola in norgestimat kot progestagen, ali pa morajo bolnice uporabljati alternativno zanesljivo metodo kontracepcije (glejte poglavji 4.4 in 4.6).
The HR for OS was 0.772 (95% CI, 0.423, 1.408; p = 0.199; median OS not reached in either arm); 85% of patients initially randomized to the placebo arm received post-progression treatment with regorafenib (see Table 7, Figure 3).
Razmerje ogroženosti v analizi celokupnega preživetja je bilo 0,772 (95-odstotni IZ, 0,423; 1,408; p = 0,199; mediana celokupnega preživetja ni bila dosežena v nobeni od skupin); 85 % bolnikov, ki so bili najprej randomizirani v skupino, ki je prejemala placebo, je bilo po napredovanju bolezni zdravljenih z regorafenibom (glejte preglednico 7, sliko 3).
The HR for these patients for PFS and OS was 1.24 (95% CI: 0.68, 2.28) and 1.09 (95% CI: 0.70, 1.70), respectively.
RO za te bolnike za PFS je bil 1,24 (95 % IZ: 0,68, 2,28), za celokupno preživetje pa 1,09 (95 % IZ: 0,70, 1,70).
The HR median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = < 0.01 to 0.03).
Srednja časa do napredovanja bolezni sta bila v teh primarnih točkah ocene učinkovitosti pri TMZ od 0,7 do 2,1 meseca daljša kot pri prokarbazinu (vrednost p testa log rank = < 0,01 do 0,03).
The Humalog 200 units/ml solution for injection in your pre-filled pen (the KwikPen) should ONLY be injected with this pre-filled pen.
Raztopino za injiciranje Humalog 200 enot/ml v vašem napolnjenem injekcijskem peresniku (KwikPen) smete injicirati SAMO s tem napolnjem injekcijskim presnikom.
The Humalog BASAL in your KwikPen is the same as the Humalog BASAL, which comes in separate Humalog BASAL cartridges.
Zdravilo Humalog BASAL v vašem KwikPenu je enako zdravilu Humalog BASAL, ki se dobavlja v posameznih vložkih zdravila Humalog BASAL.
The Humalog BASAL KwikPen comes in a pack of 5 pre-filled pens or a multipack of 2 x 5 pre-filled pens.
Humalog BASAL KwikPen je na voljo v pakiranju po 5 injekcijskih peresnikov ali kot večje pakiranje 2 x 5 injekcijskih peresnikov.
The Humalog KwikPen comes in a pack of 5 pre-filled pens or a multipack of 2 x 5 pre-filled pens.
Injekcijski peresniki zdravila Humalog KwikPen so na voljo v pakiranju po 5 injekcijskih peresnikov ali kot večje pakiranje 2 x 5 injekcijskih peresnikov.
The human coagulation factor VIII in Helixate NexGen is not extracted from human blood but is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.
Humani koagulacijski faktor VIII v zdravilu Helixate NexGen se ne pridobiva iz človeške krvi, temveč se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori humani koagulacijski faktor VIII.
The human coagulation factor VIII in Kogenate Bayer is not extracted from human blood but is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.
Humani koagulacijski faktor VIII v zdravilu Kogenate Bayer se ne pridobiva iz človeške krvi, temveč se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori humani koagulacijski faktor VIII.
The human coagulation factor VIII is not extracted from human plasma but produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.
Humani koagulacijski faktor VIII se ne pridobiva iz človeške plazme, temveč se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori humani koagulacijski faktor VIII.
The human normal immunoglobulin 10% of HyQvia may be infused either
Humani polispecifični imunoglobulin 10 % zdravila HyQvia lahko infundirate bodisi
The human normal immunoglobulin 10% should be clear and colourless or pale yellow.
Raztopina humanega polispecifičnega imunoglobulina 10 % mora biti bistra in brezbarvna ali bledo rumena.
The human oral bioavailability of emedastine is approximately 50% and maximum plasma concentrations were achieved within one-two hours after dosing.
Peroralna biološka uporabnost emedastina pri človeku je približno 50%, največja plazemska koncentracija pa je dosežena v eni do dveh urah po uporabi.
The Human Papillomavirus (HPV) types contained in the vaccine (HPV types 16 and 18) are responsible for approximately 70% of cervical cancers , 90% of anal cancers, 70% of HPV-related pre-cancerous lesions of the vulva and vagina and 78% of HPV-related pre-cancerous lesions of the anus.
Tipa humanega virusa papiloma (HPV), vsebovana v cepivu (HPV tipa 16 in 18), sta odgovorna za približno 70 % vseh primerov raka materničnega vratu, 90 % primerov raka zadnjika, 70 % primerov s HPV povezanih predrakavih sprememb vulve in nožnice ter 78 % primerov s HPV povezanih predrakavih sprememb zadnjika.
The human relevance of these findings is currently unknown.
Pomembnost teh odkritij za človeka za zdaj ni jasna.
The Humira pre-filled pen is a single-use grey- and plum-coloured pen which contains a glass syringe with Humira.
Napolnjeni injekcijski peresnik zdravila Humira je peresnik sive in temnomodre barve za enkratno uporabo, ki vsebuje stekleno brizgo z zdravilom Humira.
The Humira pre-filled pen is available in packs containing 1, 2, 4, and 6 pre-filled pens.
Napolnjeni injekcijski peresnik zdravila Humira je na voljo v pakiranjih, ki vsebujejo 1, 2, 4 ali 6 napolnjenih injekcijskih peresnikov.
The Humira pre-filled syringe is a glass syringe containing a solution of adalimumab.
Napolnjena injekcijska brizga je steklena brizga, ki vsebuje raztopino adalimumaba.
The Humira pre-filled syringe is a glass syringe with needleguard containing a solution of adalimumab.
Napolnjena injekcijska brizga je steklena brizga s ščitnikom za iglo, ki vsebuje raztopino adalimumaba.
The Humira syringe should NEVER be reused.
Brizge z zdravilom Humira NIKDAR ne smete ponovno uporabiti.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid medac to assure that they are adequately hydrated.
Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju zdravila Zoledronska kislina medac, da se prepriča, da so ustrezno hidrirani.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid Teva to assure that they are adequately hydrated.
Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju zdravila Zoledronska kislina Teva, da se prepriča, da so ustrezno hidrirani.
The hydration status of patients must be assessed prior to and following administration of Zometa to ensure that they are adequately hydrated.
Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju zdravila Zometa, da se prepriča, da so ustrezno hidrirani.
The hydrolysis of the amide moiety leading to the carboxylic acid metabolite (34 % of the dose in urine) is supported by hepatic and extra-hepatic amidase.
Hidrolizo amidnega dela, ki vodi do presnovka v obliki karboksilne kisline (34 % odmerka v urinu), omogoča amidaza v jetrih in izvennjih.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta- blockers.
Med jemanjem zaviralcev adrenergičnih receptorjev beta lahko pride do okrepljene hipertenzivne reakcije pri nagli odtegnitvi klonidina.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.
Hipertenzivni odziv na naglo ukinitev klonidina je lahko okrepljen pri jemanju zaviralcev adrenergičnih receptorjev beta.
The hypodermic injection needle must be attached to the syringe immediately prior to administration followed by volume adjustment to 5 mL.
Hipodermična injekcijska igla se mora pritrditi injekcijski brizgi tik pred aplikacijo, potem pa je treba prilagoditi volumen na 5 ml.
The hypotensive effects of dexmedetomidine may be of greater significance in those patients with pre- existing hypotension (especially if not responsive to vasopressors), hypovolaemia, chronic hypotension or reduced functional reserve such as patients with severe ventricular dysfunction and the elderly and special care is warranted in these cases (see section 4.3).
Hipotenzivni učinki deksmedetomidina so lahko bolj pomembni pri tistih bolnikih, ki že imajo hipotenzijo (še posebej, če se ta ne odziva na uporabo vazopresorjev), hipovolemijo, kronično hipotenzijo ali zmanjšano funkcionalno rezervo, na primer pri bolnikih s hudo disfunkcijo ventriklov in pri starostnikih, zato je v teh primerih potrebna posebna previdnost (glejte poglavje 4.3).
The I-Neb AAD nebuliser has been shown to be suitable for the administration of Ventavis 10 microgram/ml (1 ml ampoule with white and yellow rings).
Pokazalo se je, da je nebulator I-Neb AAD primeren za dovajanje zdravila Ventavis 10 mikrogramov/ml (1-mililitrska ampula z belim in rumenim obročem).
The I-Neb AAD system is a portable, hand-held, vibrating mesh technology nebuliser system.
Nebulator I-Neb AAD je prenosni, ročni pripomoček za razprševanje, ki temelji na tehnologiji vibrirajoče mrežice.
The Ibandronic Acid Teva film-coated tablets are white, biconvex, capsule-shaped, engraved “50” on one side and plain on the other.
Ibandronska kislina Teva filmsko obložene tablete so bele, bikonveksne, v obliki kapsul, z vtisnjeno oznako »50« na eni strani in gladke na drugi.
The ibuprofen dose is adjusted to the body weight as follows:
Odmerek ibuprofena se prilagaja glede na telesno maso:
The IC50 for dolutegravir in various labstrains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM.
Pri različnih laboratorijskih sevih je bila IC50 dolutegravirja z uporabo PBMC 0,5 nM in z uporabo celic MT-4 od 0,7 do 2 nM.
The IC50 values of abacavir against HIV-1 Group M subtypes (A-G) ranged from 0.002 to 1.179 M, against Group O from 0.022 to 1.21 M, and against HIV-2 isolates, from 0.024 to 0.49 M.
Vrednosti IC50 za abakavir proti podtipom HIV-1 skupine M (A-G) so segale od 0,002 do 1,179 M, proti skupini O od 0,022 do 1,21 M in proti izolatom HIV-2 od 0,024 do 0,49 M.
The ICGG Gaucher Registry
Register “ICGG Gaucher Registry”
The identified metabolites do not show anti-mycobacterial activity but some contribute to QTc prolongation, mainly DM- 6705.
Opredeljeni presnovki ne kažejo aktivnosti proti mikobakterijam, vendar pa nekateri prispevajo k podaljšanju intervala QTc, pretežno DM-6705.
The identified metabolites of delamanid do not show anti-mycobacterial activity.
Opredeljeni presnovki delamanida niso pokazali anti- mikobakterijskega delovanja.
The identified or potential risk of immunogenicity that might lead to immune-mediated symptoms;
o dejanski ali možni nevarnosti imunogenosti, ki bi lahko povzročila imunsko posredovane simptome;
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate)
O ugotovljenem tveganju za sinergistično hepato ali hemato toksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (disease- modifying antirheumatic drug (DMARD) zdravili (na primer metotreksat).
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate).
O ugotovljenem tveganju za sinergistično hepato ali hemato toksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (disease- modifying antirheumatic drug (DMARD) zdravili (na primer metotreksat).
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate).
O ugotovljenem tveganju za sinergistično hepato ali hemato toksičnost v povezavi s kombinirano terapijo z drugimi imunomodulirajočimi protirevmatičnimi zdravili (DMARD – disease-modifying antirheumatic drug) zdravili (na primer metotreksat).
The identity of the patient must be matched with the essential unique patient information on the infusion bag and the Final Product Disposition Notification form prior to infusion.
Pred infundiranjem je treba preveriti, ali se identiteta bolnika ujema z bistveno edinstveno informacijo o bolniku na infuzijski vrečki in obvestilom o končnem razpolaganju z zdravilom.
The IM injection is to be given slowly and deeply into the muscle and the IV bolus injection may be given rapidly and directly into a vein or into an existing IV line.
I.m. injekcijo je treba dajati počasi in globoko v mišico, i.v. bolusno injekcijo pa se lahko daje hitro in neposredno v veno ali v obstoječo intravensko pot.
The images should be viewed in a systematic manner (Figure 1) starting at the level of pons (p) and scrolling up through
Posnetke je treba pregledati sistematično (slika 1) in začeti na višini ponsa (p) ter se pomikati navzgor po
The imaging agent, technetium-99m LeukoScan [technetium-99m sulesomab] is formed by reconstitution of the contents of the LeukoScan vial with 0.5 mL sodium chloride for injection followed by the addition of 1100 MBq of sodium pertechnetate [99mTc] in 1 mL of Sodium Chloride for Injection.
Sredstvo za prikazovanje, tehnecij-99m LeukoScan (tehnecij-99m sulezomab), nastane pri rekonstituciji vsebine viale zdravila LeukoScan z 0,5 ml raztopine natrijevega klorida za injiciranje, ki ji sledi dodatek 1100 MBq natrijevega pertehnetata 99mTc v 1 ml raztopine natrijevega klorida za injiciranje.
The imaging dose of [111In]-radiolabelled Zevalin was always given immediately following an infusion with rituximab at 250 mg/m² to deplete peripheral CD20+ cells and to optimise bio- distribution.
Odmerek z [111In] označenega zdravila Zevalin za slikovni prikaz je bil vedno apliciran neposredno po infuziji 250 mg/m² rituksimaba za zmanjšanje števila perifernih celic CD20+ in optimizacijo biološke porazdelitve.
The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3 – 4 weeks in oncology patients.
Neravnovesja, ki so ga opažali v tem preskušanju, niso opažali v drugih preskušanjih z zoledronsko kislino, vključno s preskušanji z zoledronsko kislino v odmerku 4 mg vsake 3-4 tedne pri onkoloških bolnikih.
The IMBRUVICA dose should be lowered to 140 mg once daily (one capsule) when used concomitantly with moderate CYP3A4 inhibitors.
Pri sočasni uporabi z zmernimi zaviralci CYP3A4 je treba odmerek zdravila IMBRUVICA zmanjšati na 140 mg na dan (ena kapsula).
The IMBRUVICA dose should be reduced to 140 mg once daily (one capsule) or withheld for up to 7 days when it is used concomitantly with strong CYP3A4 inhibitors.
Pri sočasni uporabi z močnimi zaviralci CYP3A4 je treba odmerek zdravila IMBRUVICA zmanjšati na 140 mg na dan (ena kapsula) ali zdravljenje prekiniti za največ 7 dni.
The immediate-release part provides a rapid onset of absorption and the extended release part provides a more extended plasma profile of cortisol.
Del s takojšnjim sproščanjem zagotavlja hiter začetek absorpcije, del s podaljšanim sproščanjem pa podaljšan profil kortizola v plazmi.
The immune response after 2 doses in females aged 9 to 14 years was non-inferior to the response after 3 doses in women aged 15 to 25 years.
Imunski odziv po dveh odmerkih pri deklicah starih od 9 do 14 let ni bil nič slabši od odziva po treh odmerkih pri mladih ženskah starih od 15 do 25 let.
The immune response observed in the children 2-10 years of age was very similar to those observed in the V59P8 study shown above: immune response to Menveo at 1 month post vaccination, as measured by percentage of subjects with seroresponse, hSBA≥1:8 and GMTs, was non-inferior to ACWY-PS.
Imunski odziv, ki so ga opazili pri otrocih, starih 2–10 let, je bil podoben kot pri študiji V59P8, kot je prikazano zgoraj: imunski odziv na cepivo Menveo 1 mesec po cepljenju, izmerjen v odstotkih oseb s seroodzivom, hSBA ≥ 1:8 in GMT, ni bil inferioren od ACWY-PS.
The immune response to routine paediatric vaccines co-administered with Prevenar at different injection sites was assessed in 7 controlled clinical studies.
Imunski odgovor na običajna otroška cepiva, ki se dajejo istočasno s cepivom Prevenar, na različna mesta, so proučevali v 7 kontroliranih kliničnih študijah.
The immune response to vaccination was monitored by determining antibody titres in the vaccinated animals.
Imunski odziv na cepljenje so spremljali z določanjem titrov protiteles pri cepljenih živalih.
The immune responses to Dukoral were not studied.
Imunskega odziva na Dukoral niso raziskovali.
The immune responses to Hib (PRP) and pertussis antigens (PT and FHA) were evaluated after 2 doses in a subset of subjects receiving Hexyon (N=148) at 2, 4, 6 months of age.
Imunski odziv na Hib (PRP) in antigene oslovskega kašlja (PT in FHA) je bil ovrednoten po prejemu dveh odmerkov v podskupini, ki je prejemala Hexyon (N=148) pri starosti 2, 4 in 6 mesecev.
The immune responses to PRP, PT and FHA antigens one month after 2 doses given at 2 and 4 months of age were similar to those observed one month after a 2-dose priming given at 3 and 5 months of age: anti-PRP titers ≥ 0.15 µg/ml were observed in 73.0% of individuals, anti-PT vaccine response in 97.9% of individuals and anti-FHA vaccine response in 98.6% of individuals.
Imunski odziv na (PRP) in antigene PT in FHA en mesec po prejemu 2 odmerka, ki sta bila dana pri 2 in 4 mesecu starosti je bil sličen, kot pri podskupini, ki je prejela 2 odmerka pri 3 in 5 mesecih starosti: proti-PRP titer  0,15g/ml je imelo 73,0% posameznikov, proti-PT odziv je imelo 97,9% posameznikov in proti-FHA odziv je imelo 98,6% posameznikov.
The immune system will then be able to produce antibodies more quickly when it is exposed to the bacterium again.
Ob ponovni izpostavitvi bakteriji bo imunski sistem lahko hitreje tvoril protitelesa.
The immune system will then be able to produce antibodies more quickly when the person is naturally exposed to the viruses.
Posledično bo imunski sistem ob ponovni izpostavitvi virusu sposoben hitreje tvoriti protitelesa.
The immunogenicity 21 days after each dose has been assessed and is presented below for each age group according to the seroprotection rate, the seroconversion rate and the seroconversion factor, using haemagglutination inhibiting (HI) method.
Imunogenost po 21 dnevu po prejetem odmerku cepiva je bila določena in predstavljena v nadaljevanju za vsako starostno skupino.
The immunogenicity after two doses administered two months apart in children 6 months to 26 months of age has been documented in three studies whose results are summarised in Table 4.
Imunogenost po dveh odmerkih, danih otrokom, starim od 6 do 26 mesecev, s presledkom dveh mesecev, so ugotavljali v treh študijah, katerih rezultati so povzeti v preglednici 4.
The immunogenicity and safety of subsequent formulations of the vaccine have also been examined in studies.
V študijah so proučevali tudi imunogenost in varnost nadaljnjih formulacij cepiva.
The immunogenicity of ADVATE was evaluated in previously treated patients.
Imunogenost zdravila ADVATE so ovrednotili pri predhodno zdravljenih bolnikih.
The immunogenicity of Hexacima in children over 24 months of age has not been studied in clinical trials.
Imunogenos cepiva Hexacima pri otrocih starejših od 24 mesecev ni bila raziskana v kliničnih preskušanjih.
The immunogenicity of Hexyon in children over 24 months of age has not been studied in clinical trials.
Imunogenos cepiva Hexyon pri otrocih starejših od 24 mesecev ni bila raziskana v kliničnih reskušanjih.
The immunogenicity of IXIARO administered in a rapid vaccination schedule was evaluated in a randomized, observer-blind, phase 3 study.
Imunogenost cepiva IXIARO, odmerjenega med hitrim urnikom cepljenja, je bila ocenjena v randomizirani, za ocenjevalca slepi študiji 3. faze.
The immunogenicity of IXIARO was evaluated in an open-label, uncontrolled trial in 200 healthy elderly persons aged 65 to 83 years, including subjects with stable underlying conditions like hypercholesterolemia, hypertension, cardiovascular disease or non insulin-dependent diabetes mellitus.
Imunogenost cepiva IXIARO je bila ocenjena v odprti nenadzorovani študiji, v kateri je sodelovalo 200 zdravih starostnikov med 65. in 83. letom starosti, od katerih so nekateri imeli stabilna spremljajoča bolezenska stanja, kot so hiperholesterolemija, hipertenzija, bolezni srca in ožilja ali od insulina neodvisna sladkorna bolezen.
The immunogenicity of Kovaltry was evaluated in previously treated patients.
Imunogenost zdravila Kovaltry so ocenili pri predhodno zdravljenih bolnikih.
The immunogenicity of Menveo in children 2 to 23 months of age was evaluated in several studies.
Imunogenost cepiva Menveo pri otrocih, starih od 2 do 23 mesecev so ovrednotili v več študijah.
The immunogenicity of Nuwiq was evaluated in clinical trials in 135 previously treated patients with severe haemophilia A (74 adult and 61 paediatric patients).
Imunogenost zdravila Nuwiq so ocenili v kliničnih preskušanjih pri 135 predhodno zdravljenih bolnikih s hudo hemofilijo A (74 odraslih in 61 pediatričnih bolnikov).
The immunogenicity of PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (strain A/Vietnam/1203/2004) has been evaluated in three clinical studies in adults aged 18 – 59 years (N=961) and in older subjects aged 60 years and older (N=391) following a 0, 21 day schedule.
Imunogenost cepiva PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (sev A/Vietnam/1203/2004) je bila ocenjena v treh kliničnih študijah pri odraslih, starih od 18 do 59 let (n=961) in pri starejših osebah, starih 60 let in več (n=391), in sicer po shemi cepljenja 0. in 21. dan.
The immunogenicity of siltuximab has been evaluated using antigen-bridging enzyme immunoassay (EIA) and electrochemiluminescence (ECL)-based immunoassay (ECLIA) methods.
Imunogenost siltuksimaba so ocenjevali z encimsko imunsko metodo s povezovanjem antigenov (angl. antigen-bridging EIA - Enzyme immunoassay) in z imunsko metodo ECLIA (Electro- chemiluminescence immunoassay), ki temelji na elektrokemiluminiscenci (ECL - Electro- chemiluminescence immunoassay).
The immunogenicity of Synflorix following a 2-dose or 3-dose primary vaccination schedule in subjects less than 6 months of age was evaluated in a clinical study.
Imunogenost cepiva Synflorix za primarno zaporedje cepljenja z 2 odmerkoma ali 3 odmerki pri otrocih, mlajših od 6 mesecev so ocenili v klinični študiji.
The immunogenicity of the A/Vietnam/1203/2004 strain vaccine has been evaluated in a clinical trial in children and adolescents aged 9 to 17 years (N=288), in children aged 3 to 8 years (N=146) and in infants and children aged 6 to 35 months (N=33) following a 0, 21 day schedule.
Imunogenost cepiva cepilnega seva A/Vietnam/1203/2004 je bila ocenjena v kliničnem preskušanju pri otrocih in mladostnikih, starih od 9 do 17 let (N=288), pri otrocih, starih od 3 do 8 let (N=146) ter dojenčkih in otrocih, starih od 6 do 35 mesecev (N=33), po shemi cepljenja 0. in 21. dan.